en · de · es · fr · pt
sr9009-notes.peptides6155.com › Wiki › Background And Mechanism Of Sr9009 — Explained

Background And Mechanism Of Sr9009 — Explained

By Editorial Desk · published 2025-11-16 · last reviewed 2025-12-12 · Wiki

If you have been reading about bioavailability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Related pages on this site

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Further detail

In the case of complexes of two or more proteins, where the structures of the proteins are known or can be predicted with high accuracy, protein–protein docking methods can be used to predict the structure of the complex. Information of the effect of mutations at specific sites on the affinity of the complex helps to understand the complex structure and to guide docking methods.

== Cyber counterintelligence == Cyber counter-intelligence are measures to identify, penetrate, or neutralize foreign operations that use cyber means as the primary tradecraft methodology, as well as foreign intelligence service collection efforts that use traditional methods to gauge cyber capabilities and intentions.

=== Femarelle Recharge === Femarelle Recharge is intended for women experiencing common menopausal symptoms such as hot flashes, night sweats, sleep disturbances, and reduced quality of life during menopause. The formulation contains DT56a, flaxseed powder, and vitamin B6.

== Formulation == Ampicillin-sulbactam only comes in a parenteral formulation to be either used as intravenous or intramuscular injections, and can be formulated for intravenous infusion. It is formulated in a 2:1 ratio of ampicillin:sulbactam. The commercial preparations available include:

Sources: en.wikipedia.org

Background from the literature

Because the formation of PTH regulates the calcium level in the blood, it can affect all areas of the body. The overactivity of a parathyroid gland is known as hyperparathyroidism. It is unknown what directly causes hyperparathyroidism. However there are many factors that can cause over-secretion of PTH. The further consequence of this disorder can be osteopenia, or even osteoporosis, which is the loss of bone density. This leaves bones more porous, fragile, and likely to experience fracture. This can be detected by usage of dual-energy X-ray absorptiometry (DEXA). Interesting enough, a derivative of synthetic PTH is often given to patients with osteoporosis to combat the disease.

Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. It is also sometimes used before surgery and following a bite wound to try to prevent infection. Ceftriaxone can be given by injection into a vein or into a muscle. Common side effects include pain at the site of injection and allergic reactions. Other possible side effects include C. difficile-associated diarrhea, hemolytic anemia, gall bladder disease, and seizures. It is not recommended in those who have had anaphylaxis to penicillin but may be used in those who have had milder reactions. The intravenous form should not be given with intravenous calcium. There is tentative evidence that ceftriaxone is relatively safe during pregnancy and breastfeeding. It is a third-generation cephalosporin that works by preventing bacteria from making a cell wall. Ceftriaxone was patented in 1978 and approved for medical use in 1982. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.

== Accumulation of toxic substances == In some areas of the United States where aquatic environments have tested positive for elevated levels of toxins, such as mercury, arsenic, chromium, and copper, signs are posted with warnings about the consumption of fish caught in those areas. Concentration of mercury biomagnifies as it passes up the food chain from organisms on lower trophic levels to apex predators. It bioaccumulates in the tissues of larger, long-lived, predatory fish. When compared to smaller, short-lived fish, bowfin tend to concentrate mercury at higher levels, thereby making them less safe for human consumption.

However, this cannot be seen in experiments and the model has been widely rejected. The most accepted view is that the TCR engages in kinetic proofreading. The kinetic proofreading model proposes that a signal is not directly produced upon binding but a series of intermediate steps ensure a time delay between binding and signal output. Such intermediate "proofreading" steps can be multiple rounds of tyrosine phosphorylation. These steps require energy and therefore do not happen spontaneously, only when the receptor is bound to its ligand. This way only ligands with high affinity that bind the TCR for a long enough time can initiate a signal. All intermediate steps are reversible, such that upon ligand dissociation the receptor reverts to its original unphosphorylated state before a new ligand binds. This model predicts that maximum response of T cells decreases for pMHC with shorter lifetime. Experiments have confirmed this model. However, the basic kinetic proofreading model has a trade-off between sensitivity and specificity. Increasing the number of proofreading steps increases the specificity but lowers the sensitivity of the receptor. The model is therefore not sufficient to explain the high sensitivity and specificity of TCRs that have been observed. (Altan Bonnet2005) Multiple models that extend the kinetic proofreading model have been proposed, but evidence for the models is still controversial. The antigen sensitivity is higher in antigen-experienced T cells than in naive T cells.

=== Serotonin === In the brain, serotonin is a neurotransmitter and regulates arousal, behavior, sleep, and mood, among other things. During prolonged exercise where central nervous system fatigue is present, serotonin levels in the brain are higher than normal physiological conditions; these higher levels can increase perceptions of effort and peripheral muscle fatigue. The increased synthesis of brain serotonin occurs because of a higher proportion of tryptophan, the serotonin precursor, in the blood and which results in larger amounts of tryptophan crossing the blood–brain barrier. An important factor of serotonin synthesis is the transport mechanism of tryptophan across the blood–brain barrier. The transport mechanism for tryptophan is shared with the branched chain amino acids (BCAAs), leucine, isoleucine, and valine. During extended exercise, BCAAs are consumed for skeletal muscle contraction, allowing for greater transport of tryptophan across the blood–brain barrier. None of the components of the serotonin synthesis reaction are saturated under normal physiological conditions, allowing for the increased production of the neurotransmitter. However the failure of BCAAs to decrease time to fatigue consistently limit this hypothesis. This may be due to a counter-acting mechanism: BCAAs also limit the uptake of tyrosine, another aromatic amino acid, like tryptophan. Tyrosine is a precursor to catecholamine, which enhances performance drive.

Sources: en.wikipedia.org

Reference notes

== Discovery of Y-chromosomal markers for languages == The next development was the discovery of specific Y-chromosomal markers linked to a language. These Y-chromosomal variants do not cause language change, but happened to be carried by the historic or prehistoric male speakers spreading the language. These language-specific Y-chromosomal markers create correlations such as those observed by Poloni et al. 1997, and furthermore allow the geographic extent, the time depth and the male immigration level underlying an unrecorded (prehistoric) language change to be determined.

glycoprotein A protein with one or more carbohydrate molecules, typically short oligosaccharide chains, covalently attached to one or more of its amino acid side chains. Proteins exposed on the outer surface of the plasma membrane or secreted into the extracellular space are commonly modified in this way, after which they are said to be glycosylated.

However, Ben Kiernan and Taylor Owen suggest that "the bombs drove ordinary Cambodians into the arms of the Khmer Rouge, a group that seemed initially to have slim prospects of revolutionary success." Kissinger himself defers to others on the subject of casualty estimates: "...since I am in no position to make an accurate estimate of my own, I consulted the OSD Historian, who gave me an estimate of 50,000 based on the tonnage of bombs delivered over the period of four and a half years." A number of Republican politicians complained to Nixon that his stance on Vietnam was hurting their chances for congressional elections in November 1970, leading the president to say to Kissinger it was natural that liberals like Senator George McGovern and Senator Mark Hatfield wanted to "bug out...But when the Right starts wanting to get out, for whatever reason, that's our problem". In an attempt to change Nixon's image, Kissinger and Nixon devised the notion of a "standstill cease-fire," where both sides would occupy whatever areas of South Vietnam they were holding at the time of the ceasefire, an offer that Nixon publicly made in a television address on 7 October 1970. In his speech, Nixon apparently moved away from the "mutual withdrawal formula" the North Vietnamese kept rejecting by not mentioning it, winning much acclaim, even from his opponents like McGovern and Hatfield (though he also said the withdrawal of U.S. forces would be "based on principles" he had "previously" discussed, i.e. the "mutual withdrawal formula").

The type of analyzer used to run the CBC affects the reference ranges as well. Reference ranges are therefore established by individual laboratories based on their own patient populations and equipment.

== Background == Albericio earned his Ph.D. in chemistry from the University of Barcelona in 1981. He became a full professor at the University of Barcelona in 1995 and later served as executive director of the Barcelona Science Park from 2005 to 2012, where he was involved in field of biotechnology entrepreneurship. From 2014 to 2015, he served as the founding rector of Yachay Tech University in Ecuador. Since 2016, he has been affiliated with the University of KwaZulu-Natal in South Africa as a research professor. Albericio’s research focuses on the development of methodologies for the synthesis of peptides and other bioactive compounds. He has contributed to the design and commercialization of numerous reagents and materials used in peptide synthesis, including ChemMatrix resin and OxymaPure. Albericio was honored with the Lifetime Achievement Award at the 2024 European Peptide Synthesis Conference (EPSC) in the Czech Republic, in recognition of his contributions to the field of peptide synthesis. He also serves a editor of the International Journal of Peptide Research and Therapeutics and as a Councillor for the American Peptide Society. Throughout his career, Albericio has published extensively, with over 900 scientific articles. He has a high number of citations to his work (49,559) and an h-index of 107.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network